

Date: 13th February, 2026

To
Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

Scrip Code: 542248

Subject: Outcome of Board Meeting held on today i.e. 13th February, 2026 in terms of second proviso to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam

With reference to our Intimation vide letter dated Tuesday 10th February 2026 we wish to inform you that the Board Directors of the Company in its meeting held today i.e. Friday, 13th February 2026 through Video Conferencing have Inter-alia;

1. Considered and Approved the Standalone Unaudited Financial Results of the Company for the quarter ended 31st December, 2025 along with the Limited Review Report.
2. Considered and Approved the Consolidated Unaudited Financial Results of the Company for the quarter ended on 31st December, 2025 along with the Limited Review Report.
3. Mr. Mohak Gupta, Director of the company is authorized to sign the financial Result for the quarter ended 31st December, 2025.

Further the said outcome shall be uploaded on the website of the company at www.deccanhealthcare.co.in.

Details as required under regulation 30 of listing regulations read with SEBI circular SEBI/HO/CFD/CFDPoD 1/P/CIR/2023/123 dated July 13, 2023 are provided herewith.

The meeting was commenced at 4.30 P.M. and concluded at 4.45 P.M.

You are requested to take the information on record and oblige.

Thanking You,
Yours faithfully

For Deccan Health Care Limited


Mohak Gupta
Director



Registered Office:
6-3-347/17/5/A/Back Position,
Dwarakapuri Colony, Punjagutta,
Hyderabad – 500082, Telangana, India
Email: info@deccanhealthcare.co.in
Tel: +91 40 4709 6427

Innovation Hub & Manufacturing:
Plot No.13, Sector 03, IIE Pant Nagar,
SIDCUL, Udham Singh Nagar – 263153,
Uttarakhand, India
CIN: L72200TG1996PLC024351
www.deccanhealthcare.co.in

Date: 13th February, 2026

To,
Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001, Maharashtra

Stock Code: 542248

Subject: Submission of Standalone and Consolidated Unaudited Financial Results of the Company for the Quarter ended on 31st December, 2025 along with Limited Review Reports issued by Statutory Auditors

Dear Sir/Madam

With reference to above captioned subject and pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 31st December, 2025 along with the Limited Review Report issued by Statutory Auditors.

The said financial results were duly reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company, at their respective meetings held today.

We request you to take the same on records.

Thanking You,
Yours Faithfully,
For and on behalf of
Deccan Health Care Limited



Mohak Gupta
Director
Encl: a/a



Registered Office:
6-3-347/17/5/A/Back Position,
Dwarakapuri Colony, Punjagutta,
Hyderabad – 500082, Telangana, India
Email: info@deccanhealthcare.co.in
Tel: +91 40 4709 6427

Innovation Hub & Manufacturing:
Plot No.13, Sector 03, IIE Pant Nagar,
SIDCUL, Udham Singh Nagar – 263153,
Uttarakhand, India
CIN: L72200TG1996PLC024351
www.deccanhealthcare.co.in



Independent Auditor's Limited Review Report on Unaudited Standalone Financial Results of the Company for the Quarter and Nine months ended 31st December, 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,

**The Board of Directors of,
Deccan Health Care Limited**

We have reviewed the accompanying the statement of unaudited standalone financial results of **Deccan Health Care Limited** for the Quarter and Nine months ended **31st December, 2025** attached herewith, being submitted by the company pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement, which is the responsibility of the Company Management and approved by the Company Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by the independent Auditor of the Entity", issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primary to inquire of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit and consequently does not enable us to obtain assurance that we would become aware of all



significant matters that might be identified in an audit. Accordingly, we have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting standard ("Ind AS") and other recognized accounting practices and policies as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information require to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Keyur Shah & Associates

Chartered Accountants

F.R.No. 333288W



Akhlaq Ahmad Mutvalli

Partner

M. No. 181329

UDIN: - 26181329TERBDW1178



Date: - 13th February, 2026

Place: - Ahmedabad



DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarkapuri Colony, Somajiguda, Hyderabad, Nampally, Telangana, India - 500082

Standalone financial Results for the Quarter And Nine Months Ended on 31st December, 2025

Sr. No.	Particulars	Rs. in Lakhs (unless otherwise stated)					
		Quarter Ended			Nine Months Ended		Year Ended
		31st Dec, 2025	30th Sept, 2025	31st Dec, 2024	31st Dec, 2025	31st Dec, 2024	31st March, 2025
	Un-audited	Un-audited	Un Audited	Un Audited	Un-audited	Audited	
I	Income From Operations						
	a) Revenue from Operations	2,303.20	2,440.46	2,042.88	6,890.61	5,431.07	7,513.19
	b) Other Income	0.04	0.13	-	0.79	0.11	0.57
	Total Income	2,303.24	2,440.59	2,042.88	6,891.40	5,431.18	7,513.76
II	Expenses						
	a) Cost of Materials Consumed	1,145.27	1,583.17	1,209.62	4,633.65	2,914.51	4,096.37
	b) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	463.94	9.42	126.45	112.09	433.09	660.78
	c) Employee Benefit Expense	124.61	144.67	102.31	405.65	323.21	434.82
	d) Finance Costs	4.14	16.43	1.73	22.28	5.89	7.39
	e) Depreciation and Amortisation Expense	34.98	32.72	36.63	108.25	109.31	145.26
	f) Other Expenses	401.54	532.25	545.07	1,328.68	1,502.97	2,002.22
	Total Expenses	2,174.48	2,318.66	2,021.81	6,610.60	5,288.98	7,346.84
III	Profit/ (Loss) Before Tax (I-II)	128.76	121.93	21.07	280.80	142.20	166.92
IV	Tax Expense						
	a) Current Tax	34.95	34.58	9.08	82.70	46.57	57.01
	b) Deferred Tax (Asset)/Liabilities	(1.26)	(2.62)	(3.58)	(8.19)	(10.56)	(9.88)
	Total Tax Expense	33.69	31.96	5.50	74.51	36.01	47.13
V	Net Profit/ (Loss) After Tax for the Period (III-IV)	95.07	89.97	15.57	206.29	106.19	119.79
VI	Other Comprehensive Income/ (Loss)						
	a) Items that will not be reclassified to Profit & Loss (Net Of Tax)	3.80	3.81	(0.02)	11.41	(0.06)	15.22
	b) Items that may be reclassified to Profit & Loss (Net Of Tax)	-	-	-	-	-	-
	Total Other Comprehensive Income/ (Loss)	3.80	3.81	(0.02)	11.41	(0.06)	15.22
VII	Total Comprehensive Income/ (Loss) for the period (V + VI)	98.87	93.78	15.55	217.70	106.13	135.01
VIII	Paidup Equity Share Capital (Facevalue 10 each) Rs	2,474.92	2,474.92	2,266.58	2,474.92	2,266.58	2,342.55
IX	Other Equity						8,312.66
X	Earnings Per Equity Share- Basic/Diluted						
	Basic	0.38	0.36	0.07	0.83	0.51	0.56
	Diluted (After conversion of warrants)	0.38	0.36	0.06	0.83	0.41	0.47

Date : 13th February, 2026
Place : Hyderabad

For, Deccan Health Care Limited


Mohak Gupta
Whole-time Director
(DIN: 03534904)



DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarkapuri Colony, Somajiguda, Hyderabad, Nampally, Telangana , India - 500082

Notes to Accounts -Standalone Financial Statement

[1] The above un-audited standalone financial results for the Quarter and Nine Months ended 31st December, 2025 have been prepared by the Company in accordance with regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the board of directors in their meeting held on 13th February, 2026. A limited review of the above results has been carried out by the statutory auditors of the company.

[2] Previous Year's /period's figures have been regrouped/rearranged/ restated/adjusted/rectified/recasted wherever considered necessary.

[3] Basis of Preparation of the Statement and Adoption of Indian Accounting Standards. The Company has adopted Indian Accounting Standard (IND AS) specified under companies (Indian) Accounting Standard Rules, 2015 [as ammended] precribed under section 133 of the companies act,2013.

[4] The Company is engaged in manufacturing of nutraceutical products. Considering the nature of Business and Financial Reporting of the Company, the Company is operating in only one Segment. Hence segment reporting is not applicable.

[5] The Figure for the Quarter ended 31st December, 2025 are balancing figures between the un-audited figures in respect of Nine months ended on 31st December, 2025 and the Un-audited figures of the Half Year ended 30th September, 2025 and the figure for the quarter ended 31st December, 2024 are the balancing figure between the un-audited figures in respect of Nine months ended on 31st December, 2024 and the Un-audited figures of the Half Year ended 30th September, 2024 , which were subject to limited review.

[6] The Status of investor's complaints during the quarter ended on 31st December, 2025 as under:-

Complaints pending at the beginning of the period	Nil
Complaints received during the period	Nil
Complaints disposed during the period	Nil
Complaints resolved at the end of the period	Nil

For, Deccan Health Care Limited


MOHAK GUPTA
Whole-time Director
(DIN: 03534904) ★

Date : 13th February, 2026
Place : Hyderabad



Independent Auditor's Limited Review Report on the Unaudited Consolidated Financial Results of the Deccan Health Care Limited, for the Quarter and Nine months ended 31st December, 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors of,
Deccan Health Care Limited

We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Deccan Health Care Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), for the Quarter and Nine months ended **31st December, 2025** ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



The Statement includes the results of the following entities:

1. Beyoungstore Private Limited ("Subsidiary")

Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the statement provided by the Management related to subsidiary, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard ("Ind AS") and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The accompanying Statement includes the unaudited interim financial results/ financial information in respect of:

One Subsidiary which has not been reviewed by us, whose unaudited interim financial results reflect total revenue of Rs. 544.37 Lakhs and Rs. 834.41 Lakhs for the Quarter and Nine months ended 31st December, 2025, total profit after tax of Rs. 5.18 Lakhs and Rs. 9.08 Lakhs for the Quarter and Nine months ended 31st December, 2025 and total Other Comprehensive Income of Rs. 5.18 Lakhs and Rs. 9.08 Lakhs for the Quarter and Nine months ended 31st December, 2025, as considered in the Statement which have been reviewed by other auditors.

These interim financial results have been approved and furnished to us by the Management, and our conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such unaudited interim financial result.

Our conclusion on the statement is not modified in respect of the above matters.

For, Keyur Shah & Associates

Chartered Accountants

F.R.No. 333288W



Akhlaq Ahmad Mutvalli


Partner

M. No. 181329

UDIN: - 26181329RXXMFXM5830

Date: - 13th February, 2026

Place: - Ahmedabad



DECCAN HEALTH CARE LIMITED


CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarkapuri Colony, Somajiguda, Hyderabad, Telangana - 500082

Consolidated financial Results for the Quarter And Nine Months Ended on 31st December, 2025

Sr. No.	Particulars	Rs. in Lakhs (unless otherwise stated)					
		Quarter Ended			Nine Months Ended		Year Ended
		31st Dec, 2025	30th Sept., 2025	31st Dec, 2024	31st Dec, 2025	31st Dec, 2024	31st March, 2025
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
I	Income From Operations						
	a) Revenue from Operations	1,739.38	2,139.56	2,042.88	6,092.96	5,431.07	7,505.79
	b) Other Income	0.04	0.13	-	0.79	0.11	0.57
	Total Income	1,739.42	2,139.69	2,042.88	6,093.75	5,431.18	7,506.36
II	Expenses						
	a) Cost of Materials Consumed	515.72	1,256.63	1,209.62	3,683.91	2,914.51	4,088.97
	b) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	463.94	9.42	126.45	112.09	433.09	660.78
	c) Employee Benefit Expense	126.93	146.97	104.63	412.58	330.30	444.21
	d) Finance Costs	4.15	16.43	1.74	22.30	5.91	7.42
	e) Depreciation and Amortisation Expense	34.98	32.72	36.63	108.25	109.31	145.26
	f) Other Expenses	459.76	554.98	543.88	1,464.75	1,498.53	1,996.70
	Total Expenses	1,605.48	2,017.15	2,022.95	5,803.88	5,291.65	7,343.34
III	Profit/ (Loss) Before Tax (I-II)	133.94	122.54	19.93	289.87	139.53	163.02
IV	Tax Expense						
	a) Current Tax	34.95	33.76	9.08	82.70	46.57	57.01
	b) Deferred Tax (Asset)/Liabilities	(1.26)	(2.62)	(3.58)	(8.19)	(10.56)	(9.86)
	Total Tax Expense	33.69	31.14	5.50	74.51	36.01	47.15
V	Net Profit/ (Loss) After Tax for the Period (III-IV)	100.25	91.40	14.43	215.36	103.52	115.87
VI	Other Comprehensive Income/ (Loss)						
	a) Items that will not be reclassified to Profit & Loss (Net Of Tax)	3.80	3.81	(0.02)	11.41	(0.06)	15.22
	b) Items that may be reclassified to Profit & Loss (Net Of Tax)	-	-	-	-	-	-
	Total Other Comprehensive Income/ (Loss)	3.80	3.81	(0.02)	11.41	(0.06)	15.22
VII	Total Comprehensive Income/ (Loss) for the period (V + VI)	104.05	95.21	14.41	226.77	103.46	131.09
VIII	Paidup Equity Share Capital (Facevalue Rs 10 each)	2,474.92	2,474.92	2,266.58	2,474.92	2,266.58	2,342.55
IX	Other Equity						8,296.52
X	Earnings Per Equity Share- Basic/Diluted						
	Basic	0.41	0.37	0.07	0.87	0.49	0.54
	Diluted (After conversion of warrants)	0.41	0.37	0.06	0.87	0.40	0.45

For, Deccan Health Care Limited


Mohak Gupta
 Whole-time director
 (DIN: 03534904)

Date : 13th February, 2026
 Place : Hyderabad



DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarkapuri Colony, Somajiguda, Hyderabad, Telangana - 500082

Notes to Accounts -Consolidated Financial Statement

[1] The above un-audited consolidated financial results for the Quarter and Nine Months ended 31st December, 2025 have been prepared by the Company in accordance with regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the board of directors in their meeting held on 13th February, 2026. A limited review of the above results has been carried out by the statutory auditors of the company.

[2] Previous Year's /period's figures have been regrouped/rearranged/ restated/adjusted/rectified/recasted wherever considered necessary.

[3] Basis of Preparation of the Statement and Adoption of Indian Accounting Standards. The Company has adopted Indian Accounting Standard (IND AS) specified under companies (Indian) Accounting Standard Rules, 2015 [as ammended] precribed under section 133 of the companies act,2013.

[4] The Company is engaged in manufacturing of nutraceutical products. Considering the nature of Business and Financial Reporting of the Company, the Company is operating in only one Segment. Hence segment reporting is not applicable.

[5] The Figure for the Quarter ended 31st December, 2025 are balancing figures between the un-audited figures in respect of Nine months ended on 31st December, 2025 and the Un-audited figures of the Half Year ended 30th September, 2025 and the figure for the quarter ended 31st December, 2024 are the balancing figure between the un-audited figures in respect of Nine months ended on 31st December, 2024 and the Un-audited figures of the Half Year ended 30th September, 2024 , which were subject to limited review.

[6] The Status of investor's complaints during the quarter ended on 31st December, 2025 as under:-

Complaints pending at the beginning of the period	Nil
Complaints received during the period	Nil
Complaints disposed during the period	Nil
Complaints resolved at the end of the period	Nil

For, Deccan Health Care Limited

Mohak Gupta
★
Whole-time director
(DIN: 03534904)

Date : 13th February, 2026

Place : Hyderabad